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Abstract
Background: In Plasmodium falciparum malaria endemic areas placental malaria (PM) is an important complication of
malaria. The recurrence of malaria in primigravidae women irrespective of acquired protection during childhood is caused
by the interaction between the parasite-expressed VAR2CSA antigen and chondroitin sulfate A (CSA) in the placental
intervillous space and lack of protective antibodies. PM impairs fetal development mainly by excessive inflammation
processes. After infections during pregnancy women acquire immunity to PM conferred by antibodies against VAR2CSA.
Ideally, a vaccine against PM will induce antibody-mediated immune responses that block the adhesion of infected
erythrocytes (IE) in the placenta.
Principal Findings: We have previously shown that antibodies raised in rat against individual domains of VAR2CSA can
block IE binding to CSA. In this study we have immunized mice, rats and rabbits with each individual domain and the full-
length protein corresponding to the FCR3 VAR2CSA variant. We found there is an inherently higher immunogenicity of C-
terminal domains compared to N-terminally located domains. This was irrespective of whether antibodies were induced
against single domains or the full-length protein. Species-specific antibody responses were also found, these were mainly
directed against single domains and not the full-length VAR2CSA protein.
Conclusions/Significance: Binding inhibitory antibodies appeared to be against conformational B-cell epitopes. Non-
binding inhibitory antibodies reacted highly against the C-terminal end of the VAR2CSA molecule especially the highly
polymorphic DBL6e domain. Differential species-specific induction of antibody responses may allow for more direct analysis
of functional versus non-functional B-cell epitopes.
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Introduction
Animal models are required for preclinical development of new
generation vaccines against infectious diseases [1–3]. The ideal
animal model mimics the human immunological response, the
pathogen infection pathway, and allows analysis of the mechanism
of the vaccine-induced protective immune response. However,
despite the availability of humanised animal models such as
transgenic mice [4], immunological responses in most animal
models are only indicative of what to expect in humans. The
development of a recombinant vaccine is initiated with identifi-
cation and selection of an antigen that induces a desired immune
response. At this step, multiple antigens are tested, which requires
an inexpensive and easy to handle animal model. Following
selection of antigen, the optimal route of vaccine administration
together with a proper adjuvant formulation has to be evaluated.
The design of the individual vaccine components and their
delivery thus relies on the performance in these pre-clinical animal
tests, emphasizing the importance of the animal model.
Vaccines are one of the future strategies to prevent and control
malaria [5], one of the most widespread, pathogenic and deadly
parasitic diseases in the world. Immunity is only acquired after
successive infections in areas of high and stable malaria
transmission [6]. Pregnant women become susceptible to placental
malaria (PM) independent of any pre-existing immunity acquired
during childhood. Placental malaria can have serious consequenc-
es for both mother and child such as maternal and infant anaemia,
premature labour, low birth weight, and increased neonatal
mortality [7]. However, after successive pregnancies women
rapidly acquire immunity to PM, indicating that a vaccine
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binding of Plasmodium falciparum infected erythrocytes (IE) to
chondroitin sulfate A (CSA) present on placental syncytiotropho-
blast cells located in the intervillous space [9,10]. Placental
parasites express on the IE surface VAR2CSA, which is a
Plasmodium falciparum Erythrocyte Membrane Protein 1 (PfEMP1)
that mediates binding of the IE in the placenta [11,12].
VAR2CSA is a large (350 kDa) polymorphic protein with six
Duffy-binding-like (DBL) domains, which complicates the devel-
opment of a vaccine.
A potential animal model for studying protection induced by
immunizations with recombinant domains of PfEMP1 could be
chimpanzees (Pan troglodytes), whose natural malaria parasite,
Plasmodium reichenowi, is closely related to P. falciparum [13].
However, for ethical and economic reasons this is not a feasible
model for malaria vaccinology. To date, most malaria antigens are
produced by recombinant technology and tested in lower
mammalian species, such as rodents and rabbits. These models
have allowed analysis of antibody responses to different combina-
tions and boundaries of the six DBL-domains of VAR2CSA.
Initially, we expressed all DBL-domains fromVAR2CSA-3D7 and
found that all domains except DBL4e, could induce antibodies
against native VAR2CSA expressed on the surface of IE, with
limited differences in immunizations of mice and rabbits [14].
However, these VAR2CSA-3D7 specific sera did not show
significant inhibition of IE binding to CSA (unpublished data).
Recently, in a large screening of the immunogenicity of different
VAR2CSA antigens from the parasite line FCR3 using rat
immunizations, we found that the DBL4e domain of VAR2CSA
could elicit the desired adhesion-inhibitory antibodies [15].
However, the induction of functional inhibitory antibodies to
certain DBL-domains is poorly reproducible and the immune
response tends to focus on non-adhesion blocking epitopes [16,17].
In addition higher levels of inhibitory antibodies are acquired
using full-length VAR2CSA (FV2) as compared to single DBL-
domains [18]. To further investigate the induction of adhesion
blocking antibody responses, all single recombinant domains of
VAR2CSA-FCR3 were used in immunizations of mice, rats and
rabbits, and compared to responses raised against the full length
recombinant protein.
Results
Antigenicity of DBL-domains in three different animal
species
To examine the antigenicity of the recombinant proteins the
levels of antigen-specific IgG from immunized animals were
measured using ELISA. All animal species immunized with
individual DBL-domains or FV2 produced an IgG response, with
a typical sigmoid shaped dose response curve of the antibody
titrations (Figure 1). However, the levels of antibodies to each of
the DBL-domains as well as to FV2 differed depending on the
animal species used (for all statistical analysis of antigenic
differences see Table S2). In mice, the DBL6e immunizations
resulted in the most potent IgG response with a significantly higher
titre than that of FV2 and the other DBL-domains. Following
DBL6e in potency was DBL5e and thereafter a lower response
induced by DBL1X, DBL2X, DBL3X, DBL4e and FV2 of similar
potency. As observed in mice, immunizations of rats with DBL6e
resulted in a significantly higher IgG response compared to all
other immunogens. DBL5e and FV2 induced in rats a more
potent response than DBL1X, DBL2X, and DBL3X (Figure 1B)
but also DBL4e induced a high antibody response. In rabbits, the
seven tested antigens produced IgG responses that can be grouped
in two according to the levels of responses (Figure 1C). The
DBL6e, DBL5e and FV2 produced a high antibody response
whereas IgG responses to DBL1X, DBL2X, DBL3X and DBL4e
domains were lower and essentially similar.
In summary, the tested VAR2CSA derived recombinant
proteins induced medium to high levels of antibodies. FV2,
DBL6e and DBL5e immunizations resulted in the highest
antibody titers. FV2 appeared more antigenic in rabbits and rats
compared to mice, and only rats appeared to induce high levels of
antibodies to DBL4e.
Antibody reactivity against native VAR2CSA protein
expressed on the surface of IE
Epitopes exposed in the recombinant single-domain proteins
may not be surface exposed in the native full-length protein,
primarily due to the proposed globular folding of the VAR2CSA
molecule [19]. Therefore we tested the reactivity of the induced
Figure 1. Antibody responses to recombinant proteins in different species of animals. The reactivity of VAR2CSA-specific IgG from mice
(A), rats (B) and rabbits (C) immunized with individual domains (DBL1X-DBL6e) and FV2 is shown as the mean of all animals immunized with a
particular protein. Data are fitted to a sigmoid shaped dose response curve showing the different intrinsic antigenicity of the individual DBL-domains
and FV2. For statistical analysis see Table S2.
doi:10.1371/journal.pone.0017942.g001
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the IE.
Erythrocytes infected with the FCR3 parasite line were used in
flow-cytometry to test the IgG reactivity in animal sera against
native VAR2CSA. The parasite cultures were continuously
selected for binding to CSA by panning on BeWo cells, resulting
in surface expression of VAR2CSA and sex specific recognition by
IgG from human female serum, compared to male and Danish
serum (data not shown).
In line with the ELISA results measuring the reactivity against
the recombinant proteins, we found that the antibody reactivity
against native VAR2CSA on the surface of the IE differed both
with respect to animal species, and with antigen type. For mice
and rabbits (Figure 2A and Figure 2C), the reactivity against native
VAR2CSA on the IE surface was higher in sera from animals
immunized with DBL5e and DBL6e, the reactivity against
DBL1X, DBL2X, DBL3X and DBL4e was low. In general, it
appeared that rats acquired higher levels of antibodies specific to
the native protein compared to mice and rabbits, the difference
being especially marked for DBL4e. However, as for mice and
rabbits, the FV2, DBL5e and DBL6e immunizations resulted in
high specific reactivity towards native VAR2CSA expressed on the
IE (Figure 2B).
To test whether the reactivity against the native protein on the
IE surface was associated with the apparent antigenicity of the
recombinant domains, as measured by ELISA, the mean
fluorescence values (MFI) was correlated to the EC50 titer values
for all single domains. There was a highly significant linear
correlation for mice and rabbits (data not shown) (r=0.847,
P,0.0001 & r=0.809, P=0.0008, respectively, Pearson), whereas
the linear dependency for rats was somewhat lower (data not
shown) (r=0.476, P=0.01, Pearson).
In summary, we found high levels of concordance between
antibody reactivity against the recombinant domains and
reactivity against the native protein in serum from rabbits and
mice, but less so in serum from rats.
Functional characteristics of antibodies against VAR2CSA
domains
The proposed mechanism of protection against PM is that
antibodies block adhesion of IE to CSA in the placenta [8].
Therefore, the functional capacity of the induced antibodies was
measured in inhibition of CSA-binding assays. IE were incubated
on decorin, either with or without specific serum or purified IgG.
The specific inhibition was compared to the binding of IE
incubated with negative control samples. Only sera from rabbits
and rats were attained in sufficient volumes allowing three
independent CSA binding experiments.
The inhibitory capacity of the sera was tested prior to IgG
purification, since crude purification of IgG may introduce a bias
due to differential efficacy of purification of different antibody
isotypes. Only FV2 and DBL2X specific rabbit serum appeared to
inhibit more than the negative control rabbit serum (Figure 3A).
This was in contrast to the responses measured using FCM against
the native protein in DBL5e and DBL6e specific rabbit sera
(Figure 2C), where high reactivity was found. The inhibitory
capacity of rat serum was also not determined by the surface
reactivity, for instance there was prominent inhibition using
DBL4e and FV2 specific serum and lack of inhibition by DBL6e
specific antibodies (Figure 3A), although DBL6e specific antibodies
also were highly reactive against native VAR2CSA (Figure 2B). To
rule out that IgM or unspecific effects of serum did not mediate the
inhibitory capacity, we purified IgG from both inhibitory and non-
inhibitory sera and tested them in inhibition of binding assays at
0.5 mg/ml. The level of inhibition was essentially sustained in the
IgG preparations (Figure 3B&C).
In summary, differential induction of functional antibody
responses against DBL4e, but not to the FV2 protein, were
demonstrated in rats compared to rabbits.
Anti-FV2 IgG reactivity against individual DBL-domains
To examine how the immune response against the full-length
recombinant protein is focused with respect to individual DBL
domains, we tested the levels of antibodies against individual DBL-
domains in serum from animals immunized with FV2.
In general, we found that the pattern of antigenicity when
immunizing with FV2 was similar to immunizations with single
domains (Figure 4). In rats, FV2 antibodies targeted all DBL-
domains with similar reactivity, with exception of DBL5e and
DBL2x, which showed highest and lowest reactivity, respectively.
The levels of reactivity were more or less in line with the reactivity
against the native protein of single-domain specific antibodies
(Figure 2B). In rabbits, the reactivity against the domains appeared
to be overall lower than for rats. Furthermore, the rabbit-FV2
reactivity was more focused towards DBL5e and DBL6e, as was
also the case for the reactivity of single-domain specific antibodies
towards the native erythrocyte surface exposed protein (Figure 2C).
Figure 2. Antibody reactivity against native and surface expressed VAR2CSA. Serum from mice (A), rats (B) and rabbits (C) immunized with
individual domains (DBL1X-DBL6e) and FV2 was tested using FACS for reactivity against native VAR2CSA expressed on the surface of IE. Antibody
surface reactivity is shown for FV2 and DBL1X-DBL6e groups of animals as the median fluorescence intensity. Negative controls are serum from
animals immunized with DBL3cVAR1 and a blank sample without serum.
doi:10.1371/journal.pone.0017942.g002
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when immunizing with single domains was essentially similar to
immunizations with the FV2 protein in the different animals.
Differential recognition of DBL4e in ELISA-peptide array
analysis
The DBL4e recombinant protein appeared previously to be the
only single domain that induces highly inhibitory antibodies [15].
However, the inhibitory antibodies were not induced in rabbits.
Therefore, we tested the specificity of the antibody response in
rabbits and rats against linear epitopes using a DBL4e peptide
ELISA.
IgG induced by DBL4e immunizations reacted with the DBL4e
peptides and no reactivity was detected with IgG from control IgG
(data not shown). The overall level of reactivity was lower in rabbit
serum (n=4) compared to rat serum (n=10) and a lower
proportion of the rabbits reacted with a given peptide (data not
shown). In general, the same areas of the linear sequence were
targeted by IgG from the rats and rabbits, with the most distinct
reactivity in both species of animals observed against peptide 2 to 5
(Figure 5A). However, it appeared that the rat antibody reactivity
was skewed one to three peptides N-terminally compared to rabbit
antibodies. Hence, the major peaks of reactivity recognized by
rabbit-antibodies were peptides: 1–5, 14–19, 21–28, 31–33, 35–36
& 58–61, whereas rats recognized peptides 2–6, 14–20, 22–26,
31–38 & 60–63. Other peptides in the array were recognized by
one species only, albeit some of them with quite low OD values.
The major peak of reactivity (peptides 3–6) recognized by both
rabbit-antibodies and rat-antibodies and one minor peak with
distinct skewed reactivity (peptides 33–38) were mapped on the
structure model (Figure 5B). Both these areas of the model were
predicted to contain unstructured loops. In addition, peptide 3–6
contained a b-sheet hairpin motif and peptide 33–38 contained
several a-helixes. The other minor peak primarily targeted by rat
antibodies (peptides 61–62) was also characterized by unstructured
amino acid sequences (data not shown).
Figure 3. Comparison of surface reactivity and inhibition of FCR3-IE adhesion to CSPG. (A) Anti-VAR2CSA serum from rats and rabbits
raised against DBL1X-DBL6e and FV2 were tested using FCR3-IE for the ability of serum used in a 1:10 dilution to inhibit binding to CSA in a 96-well
plate assay. The data shown are the ratios of binding compared to the negative DBL3cVAR1 control ((Binding [test sample])/(Binding [negative
control])). (B) IgG was purified from selected inhibitory and non-inhibitory sera and tested for reactivity in FACS at 1 mg/ml. DBL3cVAR1 was used as
negative control. (C) Inhibition of binding to CSA using purified IgG at 0.5 mg/ml in the Petri dish assay. Error bars represents standard deviations.
doi:10.1371/journal.pone.0017942.g003
Figure 4. Reactivity of FV2-specific antibodies to single
recombinant DBL-domains. The data shown are pools of serum
from rats and rabbits immunized with FV2 tested in ELISA for reactivity
towards single recombinant domains of VAR2CSA and FV2. Error bars
represent standard deviations of triplicate measurements.
doi:10.1371/journal.pone.0017942.g004
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amino acid sequence of DBL4e was, apparently slightly skewed, but
otherwise remarkably similar between rabbits and rats.
Discussion
The VAR2CSA protein is a vaccine candidate against PM due
to its surface localisation, function as an adhesin for placental CSA
and its role in immunity against PM [11,20–27]. Although the full-
length protein can be produced, a vaccine based on a single
domain is more likely to be feasible, due to the complexity and size
of the antigen. To analyze if the immune responses towards single-
domains and the full-length protein were comparable, we tested all
single VAR2CSA domains as well as the full-length protein in
three different animal species.
In general, there was a direct association between antigenicity
and reactivity to the surface of the infected erythrocyte. The
reactivity against native VAR2CSA on the IE surface was higher
in sera from animals immunized with DBL5e, DBL6e and FV2
compared to other domains (Figure 2), which was similar to the
observed reactivity against the recombinant domains measured by
ELISA (Figure 1). The correlations between the antigenicity of the
domains and reactivity to the native protein on the surface of IE
were highly significant in immunization of mice and rabbits,
whereas the levels of rat antibodies reacting with the native protein
in general were higher, which resulted in a less significant
correlation. However, taken together the reactivity increased
towards the C-terminal end of the external part of VAR2CSA,
both in immunizations with single domains and FV2. This may
reflect both an inherent antigenicity of single DBL domains of
VAR2CSA and/or the accessibility of single domains in the
quaternary structure of the native VAR2CSA molecule. This is in
line with data showing that the functional CSA binding region is
located N-terminally allowing for non-blocking antibodies to react
with the C-terminal located domains (Dahlba ¨ck et al submitted).
The inhibitory capacities of the induced rat and rabbit
antibodies following FV2 immunizations were very high. Howev-
er, the different species-specific inhibitory FV2 antibodies do not
necessarily target the same epitopes, but further analysis of the
epitope targets of FV2 specific antibodies are needed to elucidate
the mechanism of inhibition. For immunizations with single
domains, the inhibition of IE binding to CSA varied between
animal species. Only rats immunized with DBL4e induced IgG,
which efficiently inhibited IE binding, whereas the rabbit sera
specific against DBL4e were non-inhibitory. The inhibitory effect
of the IgG was not an effect of antibody titer, since immunizations
with DBL5e and DBL6e also induced high titers, but these were in
general non-inhibitory. These findings are in contrast to what
others have found [21,28]. Differences in observations could be
due to different domain boundaries or to the variance in
posttranslational protein modifications introduced for example
by the baculovirus transfected T. ni as opposed to the Pichia pastoris
expression system, such as differences in glycosylation pattern.
The above findings are not likely to be caused by differences in
the MHC repertoire of the rat and rabbit strain used, since both
strains used were outbred, reducing the likelihood that all of the
individual rats and none of the rabbits induced functional
antibodies. In addition, fair levels of antibodies was induced against
the recombinant form of DBL4e in rabbits, indicating appropriate
T-cell responses during the immunizations, yet the DBL4e specific
rabbit sera was non-inhibitory even at rather high concentrations.
Differential induction of binding-inhibitory antibodies is probably
caused by species-specific differences in immuno-dominance of B-
cell epitopes in different species of animals, similar to observations
with antigens from other organisms [29,30]. Responses to FV2
appeared more homogenous between species, at least with respect
to the adhesion blocking properties, possibly due to presentation of
more epitopes in a native form compared to single domains. Since
the VAR2CSA molecule appears partly globular, immuno-
dominant B-cell epitopes, not present in the native protein, may
Figure 5. Antibody reactivity against DBL4e epitopes measured by peptide analysis. (A) Mean IgG reactivity against DBL4e peptides in
individual serum samples from rats (n=10) (Dash dot line) and rabbits (n=4) (Solid line) immunized with DBL4e recombinant protein is measured
using ELISA. Black bars represent epitopes mapped on the structure model of DBL4e. (B) The structure model of the DBL4e domain. The major peak
(p3–p6) is yellow and the minor peak (p33–p38) is red.
doi:10.1371/journal.pone.0017942.g005
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of the finding that antibodies induced against the DBL1X and
DBL3X single domains, when based on heterologous sequences,
can inhibit the binding of FCR3-IE [17], as opposed to antibodies
induced against DBL1X and DBL3X,based on the FCR3 sequence
[15].
Attempting to identify epitopes targeted by inhibitory antibod-
ies, we compared differences in rabbit and rat antibody reactivity
to linear peptides covering the entire DBL4e domain. We
previously did this with DBL4e-FCR3, DBL4e-3D7, DBL1X-
3D7 and DBL3X-HB3 specific sera from rats [17]. The average
reactivity to DBL4e linear epitopes was apparently slightly skewed
when comparing rat and rabbit antibodies. Otherwise, the
majority of responses in rats and rabbits were surprisingly similar.
This similarity, combined with the lack of functional activity of the
rabbit antibodies, both with regard to surface activity and
inhibitory capacity, probably shows that surface-reactive and
binding-inhibitory rat antibodies are not targeting linear epitopes
in the native protein. The most pronounced areas of reactivity
against the linear sequence were mapped to regions in the DBL4e
model containing unstructured loops. This is in line with the
findings that patches of high sequence diversity in VAR2CSA are
concentrated in flexible loops [20,31,32] and that naturally
acquired antibodies also are directed against these regions [33].
However, partly denatured antigen induced by Freund’s adjuvant
could increase the response to flexible loop regions in experimental
immunizations [34]. Interestingly, a fraction of the expressed
PfEMP1 during the maturation of the parasite in the IE remains
intracellular [35]. Whether this intracellular pool of protein is
denatured at the point of schizont rupture, promoting responses in
natural infections to flexible loops more tolerant to mutations, as
seen in other organisms [36], remains to be investigated.
It should be noted that DBL4e and DBL4e-ID4 specific
antibodies are cross inhibitory on a panel of maternal parasite
isolates [37], showing that a conserved region of this recombinant
protein can be targeted by antibodies interfering with the
interaction between VAR2CSA and CSA. We have not analyzed
the cross-reactivity of the FV2 induced IgG, consequently it is
unknown if the inhibitory response is directed towards conserved
or variable regions. It is possible that selection pressure can
increase exposure of immuno-dominant variable epitopes targeted
by non-inhibitory antibodies.
In summary, it appears that the immunogenicity of the
VAR2CSA protein is highest in the C terminal end, both
immunizing with single domains and with the full-length protein.
Identification of the epitopes targeted both by FV2 and DBL4e
specific bindinginhibitoryantibodies may serve as a tool to generate
second-generation antigens by removing or masking redundant/
unwanted epitopes. We do not know how the immune response will
be focused in humans upon immunization with DBL4e and the
results from a phase 1 clinical trial in human volunteers withDBL4e
will be decisive for further clinical development. Retrospectively, we
would probably not have identified the binding inhibitory capacity
of DBL4e specific antibodies had we only tested the antigen in
rabbits and mice. This emphasises the value of testing different
animal species as vaccination models, specifically for antigens like
PfEMP-1 and EBA, which have evolved to generate variations in
humoral immune responses.
Materials and Methods
Ethics statement
All procedures regarding animal immunizations complied with
European and National regulations. This study was approved by
the Danish animal welfare council under the Danish Ministry of
Justice Approval ID: 2008/561-1498.
Plasmodium falciparum culture
P. falciparum, FCR3 parasite (laboratory strain) were cultured in
RPMI–1640 supplemented with 25 mmol/L sodium bicarbonate
(Sigma–Aldrich), 0.125 mg/ml gentamycin, 0.125 mg/ml Albumax
II (Invitrogen), 2% normal human serum and with 5% hematocrit
of group 0+ human blood. To select for VAR2CSA expression, IE
were repeatedly panned on BeWo-cells as described [38]. All
isolates were mycoplasma negative and were regularly genotyped
using nested GLURP and MSP-2 primers in a single PCR step.
Protein production
All VAR2CSA single domains were cloned from genomic P.
falciparum FCR3 parasite DNA (GenBank accession
no. AY372123). Full length var2csa was based on a codon
optimized synthetic DNA fragment as described [18]. Gene
fragments were cloned into the Baculovirus vector, pAcGP67-A (BD
Biosciences) modified to contain a V5 epitope upstream of a
histidine tag in the C-terminal end of the constructs. Linearized
Bakpak6 baculovirus DNA (BD Biosciences) was co-transfected
with pAcGP67-A into Sf9 insect cells for generation of
recombinant virus particles. Histidine-tagged recombinant protein
was purified on Ni
2+ sepharose columns from the supernatant of
baculovirus infected High-Five insect cells using an A ¨KTA-express
purification system (GE-Healthcare). The full-length protein
VAR2CSA (FV2) and the six VAR2CSA DBL-domains were
produced corresponding to the following amino acid number in
VAR2CSA: FV2FCR3: 1–2649, DBL1X: 58–438 (380 aa),
DBL2X: 538–893 (355 aa), DBL3X: 1210–1587 (377 aa), DBL4e:
1583–1947 (364 aa), DBL5e: 1990–2328 (338 aa) and DBL6e:
2307–2641 (334 aa).
Animal immunizations
The animals were subcutaneously immunized with either single
VAR2CSA-domain constructs (DBL1x-6e) or with FV2. Control
groups were immunized with the DBL3c-VAR1-FCR3 in the
same concentration as the tested VAR2CSA proteins [15]. Groups
of BALB/c mice (n=8) (inbred) (Taconic, Denmark) were
subcutaneously immunized with 15 mg per animal of recombinant
protein in Freund’s complete adjuvant, followed by three follow-
up immunizations of 10 mg of protein in Freund’s incomplete
adjuvant at two-week intervals. However, due to insufficient
amounts of protein only four mice received DBL2x, and six mice
received DBL6x. For immunizations with FV2 (done on a later
time point) the mouse strain used was CB6F1 mice (F1 hybrid
between BALB/c females and C57BL/6 males) (Harlan, USA)
following the same protocol as previously described for the BALB-
c mice. Seven groups of Wistar rats (outbred) (Taconic, Denmark)
were immunized with 40 mg per animal of recombinant protein in
Freund’s complete adjuvant, followed by three booster injections
of 20 mg of protein in Freund’s incomplete adjuvant at 2K-week
intervals. The rat groups consisted of three animals except the
group receiving the DBL4e (n=8) and DBL3c (n=2). New
Zealand White rabbits (outbred)(HB Lidko ¨ping Kaninfarm,
Sweden) were immunized with 40 mg of recombinant protein in
Freund’s complete adjuvant, followed by three booster immuni-
zations of 20 mg of protein in Freund’s incomplete adjuvant at 3
week intervals. For each recombinant protein one rabbit was
immunized with the exception of rabbits receiving DBL2x & FV2
(n=2) and DBL4e & DBL5e (n=3). For all animals sera were
collected 8 days after the final immunization. Sera were stored at
220uC until use.
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ELISA plates (Nunc Immunoplate) were coated with protein
overnight (4uC) at a concentration of 1 mg/ml in 16 PBS. The
plates were blocked with ELISA dilution buffer (1% BSA and 1%
Triton x-100) before the serial diluted serum was added to the
plate. Secondary horseradish peroxidase-conjugated (HRP) anti-
bodies added in the following dilutions: anti-rabbit-IgG 1:2000
(P0448, Dako), anti-mouse-IgG 1:2000 (P0260, Dako), and anti-
rat-IgG 1:3000 (A9037, Sigma). The optical density was measured
at 490 nm in an ELISA plate reader (VersaMax, Molecular
Devices). Antibody titration curves were determined using
GraphPad Prisma5.
Affinity purified FV2 specific antibodies
The FV2-specific IgG from both rats and rabbit’s sera were
affinity purified on HiTRap
TM NHS-activated HP columns (GE
Healthcare), according to the manufacturer’s instructions. Briefly,
each column was coated with 0.5 mg/ml of a DBL-domain
resulting in six different columns for the individual six DBL-
domains. The affinity purified IgG was verified using ELISA as
previously described in this material and methods section. The
assay was performed twice with similar results.
Flow-cytometry
The reactivity of IgG in animal sera to the VAR2CSA protein
expressed on IE surface was measured by flow-cytometry (FCM)
using a protocol modified from [39]. Briefly, the parasite culture
was enriched for late trophozoite and schizont stage parasites in a
strong magnetic field (MACS, Miltenyi). Aliquots of 2610
5 IE in a
total volume of 100 ml were labelled by ethidium bromide and
sequentially exposed to (1) 15 ml animal serum and (2) 1:100
dilutions of FITC labelled secondary antibodies specific for IgG
from the individual species: Mouse (FL2000, Vector); rat (62–
9511, Invitrogen) and rabbit (FL1000, Vector). As a negative
control, IE were incubated both with sera from non-immunized
animals and without animal serum and then exposed to secondary
antibodies specific against IgG from different animals spec. Data
from 5000 infected cells (ethidium bromide positive) was collected
on a FC500 flowcytometer (Beckman Coulter). The median FITC
fluorescence intensity was determined using Winlist Software
(Verity Software House).
Inhibition of CSA-binding assay
For analyses of the capacity of serum to inhibit binding we used
2610
5 tritium-labeled late-stage IE and 15 ml serum in a total
volume of 120 ml which were added in triplicates to wells coated
with 2 mg/ml of the commercially available chondroitin sulfate
proteoglycan Decorin (D8428; Sigma-Aldrich). Decorin was used
as a source of CSA as this has a protein core resulting in more
efficient coating to plastic than CSA. After incubation for 90 min
at 37uC, unbound IE were washed away by resuspension
performed by a pipetting robot (Beckman Coulter). The
proportion of adhering IE was determined by liquid scintillation
counting on a Topcount NXT (Perkin-Elmer).
The inhibitory capacity of the induced VAR2CSA domain-
specific IgG was measured using a standardized Petri dish method
both due to the smaller volume in this assay, and because this a
more commonly used assay [40–42]. IgG was purified from the
animal sera using HiTrap Protein G HP kit (GE Healthcare) and
dialyzed against PBS 16buffer. Briefly, 20 spots in each Petri dish
(Falcon 351005) were coated overnight with 20 ml of decorin
(2 mg/ml in PBS). Spots were blocked with 3% bovine serum
albumin. Parasite cultures were enriched for late trophozoite and
schizont stages in a strong magnetic field (MACS, Miltenyi) and
adjusted to reach a 20% parasitemia at 0.5% hematocrit. The
parasite suspension was pre-incubated with both animal sera and
purified IgG at different concentrations at 37uC for 30 min.
Duplicate spots were incubated for 15 min at 37uC in a humid
chamber. Unbound erythrocytes were removed by washing with
PBS on a gyro-turntable (Stuart) until spots were clear of blood.
Bound erythrocytes were glutaraldehyde-fixed (1.5%, 5 min) and
Giemsa stained. Five fields were counted in each spot using a
magnification of 206 using a Leica Microscope. As negative
controls, anti-DBL3cVAR1 serum and IgG were used. Parasite
binding to decorin was abrogated by soluble CSA (Sigma-Aldrich)
and by chondroitinase (Sigma-Aldrich) treatment of decorin (data
not shown).
Peptide analysis
Epitope mapping was done using a peptide array covering the
DBL4e domain. The peptide array consisted of 66 synthetic 16–28
amino acids long overlapping peptides, spanning amino acids
1607–1989 of the P. falciparum-FCR3 var2csa sequence (Table S1).
The peptides were prepared by Schafer-N Copenhagen and the
purity of the peptides was expected to be 70% or higher. Peptide
binding was determined using ELISA. ELISA plates (Nunc
Immunoplate) were coated overnight (4uC) with DBL4e peptides
at a concentration of 3 mg/ml in 16PBS. Plates were blocked with
ELISA dilution buffer (1% BSA and 1% Triton x-100) before
animal serum samples were added. The serum samples were
diluted 1:100. The following secondary horseradish peroxidase-
conjugated (HRP) antibodies were used: anti-rabbit P0448
(DAKO), dilution 1:2000; and anti-rat A9037 (Invitrogen) and
diluted 1:3000. The optical density was measured at 490 nm in an
ELISA plate reader (VersaMax, Molecular Devices). The level of
reactivity in this ELISA based peptide array was directly
associated to the level of reactivity in an assay where identical
peptides were synthesised directly on to a chip, confirming
homogeneous coating of the peptides [17].
Structure modelling
The structure model of the DBL4e sequence (C1576–C1910)
was created using the same method as described for other
VAR2CSA DBL-domains [20], but using as a template the newly
published structure of DBL3X-VAR2CSA (3BQK) [43].
Statistical analyses
Best-fit curves and mean EC50 values to determine compare
antibody titres were done using Gradhpad Prism5 (Gradhpad
Software Inc.). Sigma Stat 3.11 (Sysstat software Inc.) was used in
the following analysis: one way ANOVA tests followed by multiple
pair wise comparison procedures (Holm-Sidak method), which
were used to determine differences between Log EC50 values to
measure the antigenicity of single domains and FV2; Pearson
correlation test, which was used to assess the correlation between
MFI values and OD-EC50 values.
Supporting Information
Table S1 Position and sequence of amino acids in peptides used
in the ELISA peptide array.
(DOC)
Table S2 Statistical analysis of the pattern of reactivity in ELISA
to single DBL-domains and FV2 performed for each species of
animal separately.
(DOC)
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